Can-Fite BioPharma Ltd. (CANF) Short Interest Update

Can-Fite BioPharma Ltd. (NYSEAMERICAN:CANF) was the target of a large drop in short interest in November. As of November 15th, there was short interest totalling 47,015 shares, a drop of 59.2% from the October 31st total of 115,295 shares. Based on an average daily trading volume, of 29,406 shares, the days-to-cover ratio is currently 1.6 days.

A number of equities research analysts have issued reports on CANF shares. Maxim Group reaffirmed a “buy” rating and set a $7.00 price objective on shares of Can-Fite BioPharma in a report on Friday, September 1st. HC Wainwright reaffirmed a “buy” rating on shares of Can-Fite BioPharma in a report on Tuesday, October 31st. Finally, ValuEngine lowered shares of Can-Fite BioPharma from a “sell” rating to a “strong sell” rating in a report on Thursday, September 7th.

Can-Fite BioPharma (NYSEAMERICAN CANF) opened at $1.28 on Wednesday. Can-Fite BioPharma has a fifty-two week low of $1.25 and a fifty-two week high of $2.67.

ILLEGAL ACTIVITY NOTICE: This piece was first reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this piece on another publication, it was stolen and reposted in violation of U.S. and international copyright legislation. The correct version of this piece can be viewed at https://ledgergazette.com/2017/12/13/can-fite-biopharma-ltd-canf-short-interest-down-59-2-in-november.html.

Can-Fite BioPharma Company Profile

Can Fite Biofarma Ltd is an Israel-based biopharmaceutical company. The Company develops new treatments for autoimmune diseases and cancer. The Company’s drugs are CF101 for Psoriasis treatment, RA treatment, for the treatment of Keratoconjunctictivitis Sicca, for the treatment of Glaucoma, among others; and CF102 for the treatment of liver diseases.

Receive News & Ratings for Can-Fite BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Can-Fite BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply